Evicenter
MarkdownMedical informationP&T meetings
Obefazimod (ABX464)

Ulcerative colitis

Manufacturer
Abivax
Launch
Not announced
Last updated
173 sources

Executive summary

Budget impact of Obefazimod

3 evidence topics · 15 sources

Summary

Obefazimod is investigational. Abivax states that it “has not yet been approved for commercial use in any jurisdiction”, and that the company “remains on track to submit its NDA to the U.S. Food and Drug Administration in the fourth quarter of 2026.” No FDA application has been submitted, and no peer-reviewed full publication of the ABTECT trials was identified as of November 2026. No budget impact model, cost-effectiveness analysis, or health technology assessment of obefazimod was identified, and obefazimod has no wholesale acquisition cost or average sales price. The one obefazimod price figure is an analyst assumption: LifeSci Capital, in June 2026, assumed a “net annual price at launch of US$78,000 in the U.S.”, increased from US$66,000 “based on recent management commentary”, with a 90% probability of success and market entry in 2027.

Summary: eligible population

In the United States, the age-, sex- and insurance-standardized prevalence of ulcerative colitis was 378 per 100,000 (95% CI 375 to 382), which the authors extrapolated to an estimated 1.253 million Americans using the 2020 census population. Across the study's alternative estimates, prevalence ranged from 312 per 100,000 to 438 per 100,000. ICER's 2026 Medicare assessment reports approximately 160,000 people with ulcerative colitis (0.64%) among 25 million Medicare fee-for-service beneficiaries.

ICER's 2020 review estimated its eligible population from a U.S. prevalence of approximately 900,000 patients and the Crohn's and Colitis Foundation report that approximately 22% of patients “have moderate-to-severe disease activity in a given year”, which ICER equated to approximately 198,000 patients; it assumed a fixed ratio of 55% biologic-naive and 45% biologic-experienced patients. In a Copenhagen cohort diagnosed in 2003 to 2004, early disease activity was moderate-to-severe in 24%. No more recent peer-reviewed estimate of the moderate-to-severe share was identified. Among 3,893 patients with newly diagnosed ulcerative colitis, cumulative use of advanced therapy was 17% at 1 year and 29% at 5 years, and 27% and 38% in the cohort diagnosed in 2019 to 2023.

Abivax estimates that U.S. advanced therapy use increased by approximately 96%, from approximately 138,000 patients in 2020 to approximately 271,000 in 2025, and that approximately 300,000 moderate-to-severe patients, out of an estimated 500,000, are on conventional therapy or steroids only. In company-reported research, physicians indicated they “would likely initiate treatment with obefazimod for this population”. Abivax reports U.S. ulcerative colitis sales of approximately $6.0 billion in 2025, expected to reach $14.9 billion by 2032. These figures are company estimates.

Summary: comparator costs and published budget impact methods

ICER's 2026 Medicare model, based on January 21, 2026 price estimates, gives annual net costs of maintenance of $39,423 for intravenous vedolizumab, $67,145 for subcutaneous vedolizumab, $5,430 for an intravenous infliximab biosimilar in ulcerative colitis, $78,435 for subcutaneous infliximab, and $27,221 for a subcutaneous ustekinumab biosimilar (90 mg). The Medicare negotiated price of Stelara (ustekinumab) for calendar year 2026 is $4,695.00 per 30-day supply, a 66% discount from its 2023 list price of $13,836.00. Vedolizumab (Entyvio) and tofacitinib (Xeljanz, Xeljanz XR) were selected for Medicare price negotiation, with any negotiated prices “effective beginning in 2028.” Wholesale acquisition costs of the oral advanced therapies reported to California are $6,407.16 for 60 tablets of tofacitinib 10 mg (January 2026), $6,752.77 for 30 tablets of upadacitinib 15 mg or 30 mg (January 2025), $9,289.90 for 30 capsules of ozanimod 0.92 mg (January 2025), and $6,164.38 for 30 tablets of etrasimod 2 mg at introduction (October 2023). These figures differ in date and in price basis (net, negotiated, or list).

ICER's 2020 potential budget impact analysis of ustekinumab used undiscounted costs over a five-year time horizon and a threshold of approximately $819 million per year for new drugs. Approximately 21% of eligible patients could be treated in a given year at the wholesale acquisition cost of ustekinumab, and approximately 51% at its estimated net price, without crossing that threshold. The annualized per-patient net budget impact over five years was $36,100 at list price and $15,600 at net price, against a market basket cost of $37,500. The 2020 model assumed $33,871 per admission for colectomy and $10,238 per serious infection event, and annual health-state costs of $8,048 for hospitalization, $581 for emergency department care, and $10,114 for outpatient or other care in active ulcerative colitis, against $969, $223, and $2,722 in clinical remission.